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Nonadherence to appropriately prescribed medication for psychiatric disorders prevents patients from
realizing the full benefits of their treatment and negatively impacts on individuals, their families and the
healthcare system. Understanding and reducing nonadherence is therefore a key challenge to quality care
for patients with psychiatric disorders. This review highlights findings regarding the prevalence and
consequence of nonadherence, barriers to adherence and new intervention methods from 2012 onwards.
Recent findings
Recent research has highlighted that nonadherence is a global challenge for psychiatry and has linked
nonadherence to poorer outcomes, including hospital admissions, suicide and mortality. Optimizing
medication regimens can reduce nonadherence; however, often a complex interplay of factors affects
individuals’ motivation and ability to follow their prescription. Psychiatrists can enable patients to develop
an accurate model of their illness and treatment and facilitate adherence. However, nonadherence is often
a hidden issue within consultations. Novel interventions using new technologies and tailoring techniques
may have the potential to reduce nonadherence.
Summary
Nonadherence remains a significant challenge for patients with psychiatric disorders, physicians and
healthcare systems. New developments demonstrate the importance of developing tailored interventions to
enable patients to overcome perceptual and practical barriers to adherence.
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Taking the prescribed dose of medication, at the
correct time, and for the full course of treatment is
fundamental to patients realizing the full potential
benefits of medications. However, between 30 and
50% of medicines for long-term conditions are not
taken as prescribed, resulting in costs for individual
patients and healthcare systems [1]. Research
suggests that rates of nonadherence in patients with
psychiatric disorders are comparable to those of
patients with other long-term conditions [2,3].
The Perceptions and Practicalities Approach
(PaPA) has been used to describe factors contribu-
ting to nonadherence in psychiatric disorders [4,5]
(see Fig. 1). This states that nonadherence is
the product of a range of perceptual factors (e.g.
patients’ beliefs about their illness and treatment)
and practical factors (e.g. capability and resources)
influencing their motivation and ability to start and
continue with treatment. Specifically, the model
emphasizes that, even when patients have the
ability and opportunity to take their medication
as prescribed, they may lack the motivation
to adhere. Thus, to understand and addressiams & Wilkins. Unauthononadherence, we need to view the illness and
the treatment from the patients’ perspective.
Within this approach, two key beliefs have been
implicated in the way in which medications are
prescribed: belief in personal need for medication
and concerns about the potential adverse con-
sequences of medication. This Necessity-Concerns
Framework has been found to have utility in
explaining nonadherence across long-term con-
ditions, including within psychiatric disorders [6].
Effective interventions to improve adherence
remain elusive; a recent Cochrane review has
called for more innovative interventions [7,8]. Torized reproduction of this article is prohibited.
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KEY POINTS
 Nonadherence remains a global challenge for
psychiatry that has been linked to suicide rates,
all-cause mortality and hospitalization for patients.
 Adherence to psychiatric medications is a complex,
dynamic behaviour requiring patients to initiate
treatment and continue to take their medications at the
correct time, in the correct dose, for prolonged periods
of time.
 Modifying practical barriers to adherence (e.g. dose
frequency) can reduce nonadherence; however,
patients also need to be motivated to adhere by an
informed understanding of their illness and treatment.
 A strong alliance between patients and psychiatrists
can protect against nonadherence in part by enabling
patients to develop an accurate model of their illness
and treatment.
 Effective adherence interventions remain elusive;
however, new methods of tailoring content to the
needs of individual patients combined with the use of
technologies such as electronic monitoring and SMS
may prove effective.
Medication nonadherence and psychiatry Chapman and Horneachieve this, we need to apply sound theories of the
causes of nonadherence and theories for changing
medication-taking behaviour, the why and how
of nonadherence [5]. This review will therefore
focus on recent developments from 2011 in the field
of nonadherence within psychiatric disorders, with
particular focus on the determinants of adherence
and interventions to promote adherence.NONADHERENCE IS A GLOBAL
CHALLENGE FOR PSYCHIATRY
Nonadherence to psychiatric medication is a global
problem. Recent research has highlighted non-
adherence as a key challenge to psychiatric care inCopyright © Lippincott Williams & Wilkins. Unau
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FIGURE 1. Perceptions and Practicalities Approach to
nonadherence [5].
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], Australia
[22], the Middle East [23
&
] and Africa [24
&
]. In Africa,
Alene et al. [24
&
] evaluated adherence rates to
antipsychotic medication in patients receiving care
at an Ethiopian hospital. They found that, although
52.1% reported that they had never missed a dose
or taken it outside the time instructed, only 19.6%
were fully adherent if assessed using pharmacy
refill records, illustrating that nonadherence can
be underestimated in this setting, similarly to
discrepancies shown in other settings, for example
in a South Korean sample of outpatients with
schizophrenia [25].PATTERNS OF NONADHERENCE IN
PSYCHIATRIC DISORDERS
Realizing the full benefits of an appropriately
prescribed medication is conditional on optimal
adherence. However, in practice, adherence is a
complex, dynamic behaviour; patients can be non-
adherent to their prescribed regimen because they
do not initiate, accurately maintain or persist
with their regimen. A new taxonomy of adherence
terminology has been developed to promote con-
sistency in the terminology used to describe
adherence [26
&&
]. This describes adherence as being
composed of initiation (taking the first dose of
the medication), discontinuation (no longer tak-
ing the medication) and implementation (whether
the patient’s actual behaviour corresponds to
the prescribed dosing regimen in the period
from initiation to discontinuation). Within this
taxonomy, persistence refers to the time between
initiation and the final dose of the medication.
Implementation nonadherence can include a range
of differences between the actual regimen execution
and that prescribed, including missing doses, taking
a different dose of medication than that prescribed
and taking medication at different times.
Different assessment methods can be used to
identify these differing types of nonadherence; for
example, Yang et al. [25] used pill counts to assess
whether the patient had taken the correct number
of doses, and electronic monitoring to assess
whether patients had taken these doses on sched-
ule. Other researchers have used nonpersistence
with a regimen to assess nonadherence, often using
pharmacy refill (e.g. [21
&
,27]). Through under-
standing the different aspects of adherence
measured by these assessments, we can understand
a lack of correspondence between measurements
and begin to investigate whether different patterns
of adherence have different causes and con-
sequences.thorized reproduction of this article is prohibited.
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patterns of nonadherence. Jaeger et al. [28] used
latent class analysis to group 371 inpatients with
schizophrenia on the basis of their scores on the
Medication Adherence Rating Scale at baseline,
a self-report/clinician-report tool. They identified
five groups of patients on the basis of their adher-
ence responses and found that different patterns of
adherence were associated with different rates
of later discontinuation and hospitalization. Chang
et al. [9] categorized schizophrenic patients on
the basis of type of nonadherence as measured by
pharmacy refill and found that different patterns
of nonadherence were associated with different
antipsychotic drugs. Offord et al. [21
&
] found
that patients with schizophrenia who had early
nonadherence within 90 days of starting a new
prescription had lower adherence for the following
12 months.IMPACT OF NONADHERENCE
Evidence for an impact of nonadherence on
outcomes for psychiatric patients has been con-
solidated within new research. Nonadherence has
been found to predict poorer outcomes for patients,
including hospital admission [29,30], violence
[31
&&
], suicide and premature mortality. San et al.
[30] analysed the medical records of patients with
schizophrenia/schizoaffective disorder admitted to
acute care. Of the 1646 patients on whom data were
available, for 58.6% of patients the main reason for
hospital admission was listed as nonadherence.
Nonadherence can also be a risk factor for
violence in psychosis, as confirmed by a recent
meta-analysis [31
&&
]. Witt et al. [31
&&
] found a
moderate association between violence (including
a range of measures such as reported aggression and
arrests) and adherence to medication [odds ratio
(OR) 2.0] on the basis of nine studies.
In suicide research, adherence has been
identified as the ‘strongest modifiable protective
factor’ against suicide in patients with bipolar
disorder who were followed for 10 years [32].
Lindstrom et al. [12] analysed the autopsy blood
samples of 33 patients from a psychosis clinic who
had committed suicide over a 7-year period. They
found that plasma drug levels for prescribed antipsy-
chotic and antidepressant medications suggested
that three out of 24 were nonadherent to antipsy-
chotics and 10 out of 10 were nonadherent to anti-
depressants at the time of their suicide. Similarly,
Ruengorn et al. [33
&
] used a case–control method-
ology and estimated the odds of suicide attempts in
patients with major depressive disorder as approxi-
mately twice as high for patientswith lowadherence.opyright © Lippincott Williams & Wilkins. Unautho
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premature mortality in schizophrenia [34
&
]. Cullen
et al. [34
&
] retrospectively examined the records of a
cohort of US patients with schizophrenia and found
that low adherence to antipsychotics predicted
mortality. As with previous research showing an
association between mortality and adherence [35],
it is unclear whether adherence per se is contributing
to reduced mortality, or whether it is a marker
for other factors. For example, as stated above,
adherence could have a direct effect on psychiatric
outcomes and associated risk. However, adherence
may be a marker for a more direct causal effect,
for example good social support or a tendency to
engage in health behaviours, including exercise.NONADHERENCE IS OFTEN A HIDDEN
PROBLEM
It is very difficult for practitioners to guess which of
their patients are nonadherent [11,23
&
,36]. Olivares
et al. [23
&
] surveyed 4722 psychiatrists across
36 countries. Psychiatrists estimated that 53%
of their patients with schizophrenia were non-
adherent, suggesting that they recognized the
importance of nonadherence. However, identifying
the particular patients who are not adherent may be
a particular challenge. Stephenson et al. [37
&&
] asked
US physicians to rate the adherence of individual
patients with bipolar disorder and/or schizophrenia,
and found that 72% of patients whose prescription
refill records indicated nonadherence were rated as
adherent by their physician. Thus, there is evidence
that nonadherence may be recognized as a general
problem but remains hidden within individual
consultations. Patients may fear that physicians
will interpret a lack of faith in their medicine as
representing a lack of faith in them, and therefore
be reluctant to raise their concerns and doubts with
their physicians.
A strong, trusting relationship between patients
and physicians may therefore protect against non-
adherence, as confirmed by a new meta-analysis
that found that, where the alliance between
clinicians and patients was strong, patients were
more likely to adhere [38
&
]. Thompson and McCabe
[38
&
] identified 23 studies relevant to this topic
and suggested that future studies should focus on
objective assessments of the content of clinical
interactions. In one study that did directly assess
consultation content, Quirk et al. [39
&&
] analysed
recordings of 92 consultations that contained
discussion of antipsychotic medications between
patients and nine UK psychiatrists. Nonadherence
was disclosed in 22 consultations and most
frequently resulted in a prescription change inrized reproduction of this article is prohibited.
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&&
].
The researchers suggest that physicians may avoid
risking conflict around medication adherence
in order to maintain patients’ engagement with
treatment. However, research on the causes of
nonadherence suggests that addressing patients’
doubts and concerns about medication directly
may be essential to supporting adherence [6,40,41].Content
Delivery
vehicle
Context
Adherence
support
interventions
FIGURE 2. Intervention components, based on content from
[5].DETERMINANTS OF NONADHERENCE
Some medication regimens appear to be associated
with greater adherence due to specific features of
the medication, such as side effect profiles [27]
or reduced dosing frequency (as shown by recent
systematic reviews) [42,43]. However, even where
regimens are optimized for adherence by reducing
the number or frequency of doses, motivation is still
required to maintain full adherence.
Within the PaPA, adherence to medication is
determined by both practical factors (e.g. resources,
patient capacity) and perceptual factors (e.g. beliefs
about treatment and illness) (see Fig. 1). Hence,
attempts to improve adherence by tackling practical
barriers alone may not be successful if perceptual
barriers (e.g. doubts about medication necessity or
concerns about adverse consequences) are salient
for individuals. Staring et al. [44] found that a lack of
insight, and in particular low recognition of the
need for treatment, was strongly associated with
nonadherence within a sample of patients with
schizophrenia. This effect was particularly strong
when patients had good verbalmemory. Evenwhere
practical barriers are important, they may reinforce
or overlap with perceptual barriers. For example,
a cross-sectional survey of 24017 US patients
with chronic illnesses, including depression, found
that perceptual factors predicted reported un-
intentional nonadherence (e.g. forgetting, running
out of medication, affordability), suggesting that
motivational factors can impact on both perceptual
and practical barriers to adherence [45].
The key role of medication beliefs in adherence
is illustrated by a recent qualitative synthesis
of research on this topic in patients with
schizophrenia, which highlighted beliefs about
control, dependence and stigma [46]. Richardson
et al. [47] conducted a meta-analysis of the associ-
ation between medication attitudes and adherence
in patients with psychoses, finding 14 studies
indicating a small to moderate association. A need
for more prospective and intervention studies
was identified. Patients with a lack of insight into
their psychiatric disorder have also been found
to be at risk of nonadherence [13]. These studies
demonstrate that motivational factors extendCopyright © Lippincott Williams & Wilkins. Unau
0951-7367  2013 Wolters Kluwer Health | Lippincott Williams & Wilkbeyond knowledge of medication efficacy and
adverse effects.
Comorbid psychiatric conditions can them-
selves be risk factors for nonadherence. Depression
and substance abuse have both been linked to
nonadherence within patients with psychiatric
diagnoses [32,48
&&
,49
&
]. Psychiatric comorbidity is
also a risk factor for nonadherence in physical
disorders. Kronish et al. [50
&
] found that veterans
with post-traumatic stress disorder (PTSD) had
increased odds of nonadherence to all medications,
relative to veterans without PTSD (OR 1.47), partly
due to increased concerns about the potential
adverse effects of treatment [51]. Similarly, Rao
et al. [52] found that nonadherence in HIV patients
was predicted by symptoms of depression, which
were also associated with increased perceived
HIV stigma. Comorbid psychiatric conditions may
therefore impact on both practical barriers to adher-
ence (e.g. through increased regimen complexity)
and perceptual barriers (e.g. through increased
concerns).NEW DEVELOPMENTS IN ADHERENCE
INTERVENTIONS
Adherence interventions require three key com-
ponents: content (e.g. information, feedback),
delivery vehicle (e.g. face-to-face nurse support,
telephone calls, e-mail) and a broader context (e.g.
primary care setting, inpatient care); see Fig. 2 [5].Intervention content
New developments have focused on intervention
content, in particular tailoring, cognitive beha-
vioural therapy (CBT) techniques and financial
incentives. Sajatovic et al. [53,54] found improve-
ments in adherence in a group of patients with
bipolar disorder who were screened on factors
including attitudes towards their medicines andthorized reproduction of this article is prohibited.
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ever, a fully controlled trial is needed before strong
conclusions can be drawn regarding the utility
of this tailoring process. Gleeson et al. [55]
addressed medication adherence as part of relapse
prevention therapy for first-episode psychosis, a
CBT-based intervention composed of 7 months
of fortnightly individual therapy sessions along
with family intervention. They found that medi-
cation adherence improvements were sustained at
30 months of follow-up. The use of financial incen-
tives in order to motivate adherence is one strategy
that a new systematic review has indicated may
be effective across long-term conditions, including
psychiatric disorders [56]. However, questions
remain regarding the ethics of this approach, in
particular the implications for informed choice
relating to treatments wherein there is potential
for harm as well as benefit.Delivery vehicle
Novel methods of delivering interventions have
been applied within psychiatric settings, including
computerized decision tools [57
&
], electronic
monitoring and feedback [58
&&
], SMS [15
&&
] and tele-
monitoring [59]. Results from these approaches are
promising, but the evidence for efficacy is mixed.
Montes et al. [15
&&
] reported improvements in adher-
ence for patients with schizophrenia who were sent
3 months of daily SMS reminders; however, patients
were only followed for 3 months postintervention
and a substantial proportion of intervention
patients who did not receive all SMS messages were
excluded from the sample. Velligan et al. [58
&&
]
found that patients with schizophrenia who were
given electronic pill cap reminder devices had
equivalent improvements in adherence to those
given 30min of individualized support per week
for 9 months. However, they found higher drop-
outs in the electronic pill cap condition and did not
follow up patients postintervention. Questions
therefore remain about whether these new interven-
tion delivery vehicles are suitable for all patients,
and whether they result in long-term improvements
in adherence.Intervention context
Intervention content and delivery may need to be
contextualized to environmental factors, including
cultural variation. For example, Read [60
&
] con-
ducted qualitative interviews with patients taking
antipsychotic medication in Ghana, and high-
lighted reasons for nonadherence, including side
effects impacting on the ability to perform physicalopyright © Lippincott Williams & Wilkins. Unautho
450 www.co-psychiatry.comwork, and a desire for a permanent ‘cure’ rather
than a maintenance therapy. Thus, particular
beliefs may be more relevant to some individuals
within particular settings. However, it is important
to recognize that variations in treatment percep-
tions and behaviours such as adherence are likely
to be greater within cultural groups than across
groups [61]. Hence, intervention content should
be tailored to the individual rather than across a
cultural group. Kopelowicz et al. [62
&&
] reported a
culturally adapted family intervention for Mexican
American patients with schizophrenia, which
improved adherence at 12 months postinterven-
tion, illustrating ways in which the intervention
content and delivery can be addressed to barriers
specific to the patient group without relying on
generalizations about which barriers patients would
face on the basis of their background. For example,
they tailored intervention content on the basis
of the outcomes from individual interviews
with patients. By personalizing intervention con-
tent based on individual attitudes, the researchers
ensured culturally relevant content without making
generalizations about the typical beliefs held by a
specific group.
In summary, new interventions have been
developed, and questions around their long-term
effectiveness and relevance across diverse patient
groups remain. In addition, one key challenge for
adherence intervention development is to system-
atically describe intervention components to enable
researchers to isolate the effective components
of interventions and facilitate understanding
and replication interventions [7]. For example,
currently, both or neither of two interventions
described as psychoeducational may address con-
cerns about side effects. Within the field of beha-
viour change, a taxonomy to describe intervention
components has been developed over recent years
[63
&&
], which may be applicable to adherence inter-
ventions. By understanding the processes and active
components within effective interventions, we may
be able to open the ‘black box’ of intervention
techniques and produce brief interventions tailored
to the needs of individual patients [7].CONCLUSION
Nonadherence remains a challenge for patients
with psychiatric disorders, their physicians and
healthcare providers, resulting in poorer outcomes
for patients. New developments in the field of psy-
chiatry shed light on key modifiable determinants
of nonadherence within psychiatric disorders.
Using this understanding to build theories of both
adherence and behaviour change is a key challengerized reproduction of this article is prohibited.
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Medication nonadherence and psychiatry Chapman and Horne[5]. New technologies may also be able to support
adherence within low-resource settings.
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